Efficacy and Biomarker Explanation of AK-112 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2023-03-25
• Target enrollment: 0
• Participant gender: All

Summary

This study aimed to explore the efficacy and biomarker explanation of AK112 Plus Lenvatinib on extensive stage small cell lung cancer who failed from first line Atezolizumab plus platinum based chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hunan Province Tumor Hospital
• Treatments: Lenvatinib

Criteria

Inclusion Criteria:

• Age ≥ 18 years of age on day of signing informed consent.

• Pathological revealed extensive stage small cell lung cancer.

• Patients who failed from first line Atezolizumab plus platinum based chemotherapy

Exclusion Criteria:

• Patients with contraindication of chemotherapy Pregnant or breast feeding women